COVID-19 and the FDA Emergency Use Authorization Power
This blog post provides an overview of the FDA’s emergency authorization powers and analyzes the extent of their usage in the COVID-19 pandemic.
pharma
-
Read more: COVID-19 and the FDA Emergency Use Authorization Power -
Read more: How are COVID-19 Vaccine Manufacturers Building Trust in the FDA’s Approval Process? How are COVID-19 Vaccine Manufacturers Building Trust in the FDA’s Approval Process?
Pharmaceutical companies are now also engaging the public themselves in an attempt to build trust in their products.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Selections feature topics ranging from political pressures facing the FDA, to the financial incentive structure for antibiotic development.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on pharma, health law, and policy issues from August 2020.
-
Read more: How Does Moderna’s COVID-19 Vaccine Work, and Who Is Funding Its Development? How Does Moderna’s COVID-19 Vaccine Work, and Who Is Funding Its Development?
Moderna’s vaccine works using a completely novel mechanism, unlike any other vaccine currently approved anywhere in the world.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from July 2020.
-
Read more: COVID-19 Vaccine Advance Purchases Explained COVID-19 Vaccine Advance Purchases Explained
No vaccine for the novel coronavirus has been approved. Nevertheless, governments and organizations are making deals for tens of millions of doses.
-
Read more: How Can the US Address Coronavirus Drug Shortages? How Can the US Address Coronavirus Drug Shortages?
With the sudden spike in hospitalized patients with COVID-19 symptoms, physicians are using these drugs faster than manufacturers are making them.
-
Read more: What Does It Mean That Oracle is Partnering with the Trump Administration to Study Unproven COVID-19 Drugs? What Does It Mean That Oracle is Partnering with the Trump Administration to Study Unproven COVID-19 Drugs?
Cross-posted from Written Description, where it originally appeared on March 30, 2020. By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob Sherkow One of the dizzying stream of innovation and health law stories to emerge last week is Oracle’s partnership with the White House to study unproven pharmaceuticals for treating COVID-19. We decided to unpack this story for ourselves and then…
